anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Young children with autism experience severe deficit in joint attention skills (e.g. pointing to objects, showing, following another person's gaze, responding to invitations to social interaction). Ability to initiate and respond to joint attention is linked to children's later language abilities. As a mean to improve language outcome in children with autism, it is important to target joint attention in early intervention programs.

This study investigates the effectiveness of a joint attention intervention. Sixty 2-4 year old children with autism will be randomized to an intervention group or a control group. Children in both groups will continue their ordinary preschool program. However, the children in the intervention group will also participate in 80 joint attention intervention sessions. The sessions (20 minutes each) will be conducted twice a day for 8 weeks by preschool teachers or paraprofessionals working in the preschools. Before starting the intervention preschool teachers and paraprofessionals will be taught how to teach joint attention skills and how to initiate and maintain episodes of joint engagement. During the course of intervention they will be supervised by trained counselors.

Outcome measures will include joint attention skills, language skills and joint engagement. Children will be assessed at baseline, after 10 weeks and at follow up 6 months and 1 year after the end of the intervention. The measures are based on direct testing of the children, video observations and questionnaires to parent and professionals.
The formulation, to be understood as a basic composition for preparing 100 grams of product, consists of white Vaseline 15 grams, Vaseline oil 6 grams, polysorbate 60, 4 grams, sorbitan monostearate 12 grams, monohydrated monosodium phosphate 0.538 grams, dodecahydrated disodium phosphate 0.15 grams, methylparaben 0.1 grams, glycerol 5 grams and as much purified water as is needed to reach 100 cc. To prepare the product, using a blender with heating apparatus, one first melts together the white Vaseline, the Vaseline oil, the polysorbate 60 and the sorbitan monostearate at approximately 60 degrees while in a separate beaker the phosphates are dissolved in approximately 40 ml of water by heating. The methylparaben is separately dissolved in approximately 15 ml of water at around 80 degrees. The aforesaid solutions are combined, one then adds the glycerine and brings up the volume to the proper level. The compound is then heated at 60 degrees and the aqueous phase is mixed into the oil phase, emulsifying for 15/20 (fifteen/twenty) minutes. In particular, said aqueous part may be approximately 5 degrees higher than the oil part.
An identification system and method for medication management comprises a controller, a drug library accessible by the controller, the drug library containing drug library profiles including a data set of drug information, and an identification module configured to read patient identification information from machine- readable identification devices worn by patients and to read drug information from machine-readable identification devices affixed to drugs or containers of drugs. The controller compares the read information to each other and to the drug library profile and provides alerts or error signals in the event of an inconsistency. In one case, identification devices are read by an optical reader fixedly mounted to the identification module. In another case, identification devices are read by an optical reader that is hand-held and mobile and can be moved to the location of the identification device. The hand-held reader communicates with the identification module by wired or wireless means. In another case, a third reader that is non-optical and wireless is fixedly mounted to the identification module. The controller is also configured to provide alerts or error messages in the event that there is an inconsistency between the drug information on the drug or drug container when compared to the drug library profile associated with the controller.
In phase I study , 9 enrolled patients diagnosed with advanced liver cancer will receive one-time transhepatic arterial infusion of fhB7H3.CAR-Ts at the doses of 1×10\^6/kg, 3×10\^6/kg and 5×10\^6/kg, 3 patients for each dose. To further confirm the therapeutic efficacy, in phase II study, 6 enrolled patients will receive an optimal dose (balancing effectiveness and toxicity) of fhB7H3.CAR-Ts.
Caution should be employed in the repeated use of Lidocaine Hydrochloride Injection, USP in patients with severe liver or renal disease because accumulation may occur and lead to toxic phenomena since Lidocaine Hydrochloride Injection, USP is metabolized mainly in the liver and excreted by the kidneys. This drug should also be used with caution in patients with hypovolemia and shock and all forms of heart block (see CONTRAINDICATIONS and WARNINGS). 

In patients with sinus bradycardia or incomplete heart block, the administration of Lidocaine Hydrochloride Injection, USP intravenously or the elimination of ventricular ectopic beats without prior acceleration in heart rate may promote more frequent and serious ventricular arrhythmias or complete heart block. (See CONTRAINDICATIONS.) 

Many potent anesthetic drugs, neuromuscular blocking agents and possibly amide local anesthetics may serve as triggering agents for the fulminant hypermetabolic process termed malignant hyperthermia. Key to successful outcome of fulminant hypermetabolism is early recognition of premonitory signs, i.e., unexplained or unexpected tachycardia and increased metabolic rate as evidenced by respiratory and/or metabolic acidosis. Treatment includes administration of oxygen and discontinuation of lidocaine hydrochloride administration and where necessary administration of dantrolene sodium. For additional information on management, see prescribing information for dantrolene sodium.
Participants will consume cellulose capsules that are similar in shape and size to the NO ultra product, i.e. 2 capsules between breakfast and lunch and 2 other capsules between lunch and dinner.
This is the only arm of the study. All 12 participants will undergo the insertion of the magnetic-tipped guidewire into their nasogastric tube after its correct placement is confirmed by chest X-ray.
Patients are planned for urgent operation, that should be done within 8 hours. Operation can be done during the night time. Patients do not receive antibiotics while waiting surgery. Prophylactic antibiotics are given 0-30 minutes before incision.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to traumatology, physiotherapy. Method includes peri-articular subcutaneous introduction of ozone-oxygen mixture. After that, introduction of karipain is carried out. For this purpose electrostimulator electrode is connected to needle, through which ozone-oxygen mixture was introduced. The second electrostimulator electrode is wrapped with napkin soaked with karipain solution and installed in popliteal space. Pulse current impact is realised through electrodes. Current amount is 7-10 mA, frequency - 50 Hz, pulse duration - 0.3 sec. Impact is realised for 10-15 minutes. Procedures are carried out daily. Course includes 12-15 procedures. ^ EFFECT: method ensures long positive result due to recovery of knee joint function, stopping pain syndrome and reduction of inflammatory response of knee joint structures. ^ 1 ex
The invention provides a drug pillow and relates to bedclothes, in particular to a drug pillow and provides the drug pillow with a Chinese medicinal herb pillow core. The drug pillow is composed of a pillow sleeve and a pillow core. The Chinese medicinal herb is placed in the pillow core. The drug pillow is characterized in that chrysanthemum, folium mori, a magnet, bomeol, field mint, chastetree fruit, radix angelicae, ligusticum, red flower, notopterygium root, the root of kudzu vine and ligusticum wallichii are arranged in the Chinese medicinal herb placed in the pillow core of the drug pillow. The drug pillow is low in cost. The drug pillow has functions of preventing diseases, curing diseases and fitness. The drug pillow plays a role in auxiliarily curing headache and dizziness caused by cervical spindylosis and hypertension.
Two multicenter, double-blind, active-controlled, randomized, eight week studies were conducted in patients with endoscopically confirmed EE. Severity of the disease was classified based on the Los Angeles Classification Grading System (Grades A-D). Patients were randomized to one of the following three treatment groups: dexlansoprazole delayed-release capsules 60 mg once daily, dexlansoprazole delayed-release capsules 90 mg once daily or lansoprazole 30 mg once daily. Patients who were H. pylori positive or who had Barrett's Esophagus and/or definite dysplastic changes at baseline were excluded from these studies. A total of 4092 patients were enrolled and ranged in age from 18 to 90 years (median age 48 years) with 54% male. Race was distributed as follows: 87% Caucasian, 5% Black and 8% Other. Based on the Los Angeles Classification, 71% of patients had mild EE (Grades A and B) and 29% of patients had moderate to severe EE (Grades C and D) before treatment.

The studies were designed to test noninferiority. If noninferiority was demonstrated then superiority would be tested. Although noninferiority was demonstrated in both studies, the finding of superiority in one study was not replicated in the other.

The proportion of patients with healed EE at Week 4 or 8 is presented below in Table 8.

*Based on crude rate estimates, patients who did not have endoscopically documented healed EE and prematurely discontinued were considered not healed.  
† Patients with at least one postbaseline endoscopy.  
‡ Primary efficacy endpoint.  
§Demonstrated noninferiority to lansoprazole.

Dexlansoprazole delayed-release capsules 90 mg once daily was studied and did not provide additional clinical benefit over dexlansoprazole delayed-release capsules 60 mg once daily.
In chronic lymphocytic leukemia (CLL), survival of neoplastic cells depends on microenvironmental signals at lymphoid sites where the crosstalk between the integrin VLA-4 (CD49d/CD29), expressed in ~40% of CLL, and the B-cell receptor (BCR) occurs. Here, BCR engagement inside-out activates VLA-4, thus enhancing VLA-4-mediated adhesion of CLL cells, which in turn obtain pro-survival signals from the surrounding microenvironment. We report that the BCR is also able to effectively inside-out activate the VLA-4 integrin in circulating CD49d-expressing CLL cells through an autonomous antigen-independent BCR signaling. As a consequence, circulating CLL cells exhibiting activated VLA-4 express markers of BCR pathway activation (phospho-BTK and phospho-PLC-γ2) along with higher levels of phospho-ERK and phospho-AKT indicating parallel activation of downstream pathways. Moreover, circulating CLL cells expressing activated VLA-4 bind soluble blood-borne VCAM-1 leading to increased VLA-4-dependent actin polymerization/re-organization and ERK phosphorylation. Finally, evidence is provided that ibrutinib treatment, by affecting autonomous BCR signaling, impairs the constitutive VLA-4 activation eventually decreasing soluble VCAM-1 binding and reducing downstream ERK phosphorylation by circulating CLL cells. This study describes a novel anchor-independent mechanism occurring in circulating CLL cells involving the BCR and the VLA-4 integrin, which help to unravel the peculiar biological and clinical features of CD49d+ CLL.
The nucleotide binding oligomerization domain containing 2 (NOD2) protein and its ligand N-acetyl muramyl dipeptide (MDP) are crucially involved in Crohn's disease (CD). However, the mechanism by which NOD2 signaling is regulated in CD patients remains unclear. Ubiquitin specific protease (USP14) is a deubiquitylase that plays an important role in immunity. This study aimed to investigate the mechanism by which UPS14 regulates NOD2 induced inflammatory response in CD and inflammatory bowel diseases (IBD). Our results showed that USP14 protein and mRNA levels in intestinal tissues of CD patients were significantly higher than those in healthy controls. In addition, USP14 was upregulated in IBD mouse model. While treatment with MDP, TNF-α or the Toll-like receptor 1/2 agonist Pam3CSK4 all led to significantly higher mRNA levels of TNF-α, IL-8 and IL-1β in THP-1 cells, pretreatment with USP14 inhibitor IU1 could stimulate further upregulation of TNF-α, IL-8 and IL-1β. In particular, MDP promoted the activation of JNK, ERK1/2 and p38 as well as NF-kB in THP-1 cells, and IU1 significantly enhanced the MDP-induced activation of these proteins without effects on USP14 protein level. Furthermore, the JNK inhibitor sp600125, ERK1/2 inhibitor U0126 or P38 MAPK inhibitor PD169316 significantly decreased the mRNA levels of TNF-α, IL-8 and IL-1β in THP-1 cells stimulated by both IU1 and MDP. In conclusion, our findings suggest that USP14 could inhibit MDP-induced activation of MAPK signaling and the inflammation response involved in IBD, and that USP14 is a potential therapeutic target for IBD.
An antibacterial medical biomaterial includes an acellular small intestinal submucosal matrix material, an antibacterial gel layer located on a surface of the acellular small intestinal submucosal matrix material, and an absorbable fiber layer located on a surface of the antibacterial gel layer. Sulfadiazine silver is on the surface of the acellular small intestinal submucosal matrix material and/or within the acellular small intestinal submucosal matrix material. An absorbable fiber layer to which the sulfadiazine silver is attached, wherein the content of sulfadiazine silver in the absorbable fiber is 1 wt. %˜2 wt. %. The medical biomaterial is usable as an external medicine for treating wound infections relayed by burns or wounds, and for reducing the incidence of infection by using a conventional central venous catheter with a sulfadiazine silver antibacterial coating, so that the medical biomaterial loaded with sulfadiazine silver also has antibacterial activity consistent with sulfadiazine silver.
Combination EE/DRSP/ Metafolin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin\] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
Examine the effect of ICG on the kinetics of the hepatic transport of 11C-CSar. If no effect is seen on the kinetics, ICG will be used during the "infusion method" experiments.
Primary glomerular diseases are rare entities. This has hampered efforts to better understand the underlying pathobiology and to develop novel safe and effective therapies. NEPTUNE is a rare disease network that is focused on patients of all ages with minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy. It is a longitudinal cohort study that collects detailed demographic, clinical, histopathologic, genomic, transcriptomic, and metabolomic data. The goal is to develop a molecular classification for these disorders that supersedes the traditional pathological features-based schema. Pediatric patients are important contributors to this ongoing project. In this review, we provide a snapshot of the children and adolescents enrolled in NEPTUNE and summarize some key observations that have been made based on the data accumulated during the study. In addition, we describe the development of NEPTUNE Match, a program that aims to leverage the multi-scalar information gathered for each individual patient to provide guidance about potential clinical trial participation based on the molecular characterization and non-invasive biomarker profile. This represents the first organized effort to apply principles of precision medicine to the treatment of patients with primary glomerular disease. NEPTUNE has proven to be an invaluable asset in the study of glomerular diseases in patients of all ages including children and adolescents.
A method of preserving haptenized tumor cells is described. The method employs a freezing medium containing an effective amount of sucrose and human serum albumin in an isotonic buffered saline solution. Cryogenically preserving haptenized cells in such a medium has been found to maintain the integrity of the tumor cells during storage. The haptenized tumor cells also retain cell-associated antigens and haptens, and are as immunogenic, i.e., capable of inducing immunotherapeutic response, as fresh vaccine in a mouse model of metastatic disease. In a specific embodiment, haptenized cells are exposed to a solution of 8% sucrose, 10% human serum albumin in Hank's buffered solution, and then frozen to −80° C. overnight and then stored in a liquid nitrogen freezer. Methods of storing haptenized tumor cells and compositions are also provided.
1420788 Radioactive preparations SOLCO BASEL AG 7 May 1973 [8 May 1972 8 Feb 1973] 21639/73 Heading G6R An injectable preparation of Tc99m or In113m of high specific activity per unit volume is made by mixing a sparingly soluble metal hydroxide with a low activity solution of the radionuclide, separating the metal hydroxide with the radionuclide concentrated therein, and dissolving the metal hydroxide in a small volume of an aqueous solution of a compound which will form a chelate with the metal. The metal hydroxide may be ready-formed or may be precipitated in the low activity solution by adding a solution of a metal compound followed by an alkali. Hydroxides of Fe(II), Fe(III), Ca, Mg and Al are prepared, but hydroxides of Cr(III), Yb(III) and Co(III) are also referred to. The chelating agent may be ascorbic, citric, or lactic acid, or alternatively, ethylenediaminetetraacetic acid or diethylenetriaminepentaacetic acid, together with hydrochloric and/or acetic acid. Further examples of suitable chelating agents are given. A solution of a citrate, citrate/phosphate, or tris-(hydroxymethyl) aminomethane may be added as a buffer solution to the separated metal hydroxide either before or together with the chelateforming solution.
BACKGROUND AND OBJECTIVE: Pregnant mothers are at risk of many adverse pregnancy outcomes, including infants with low birth weight (LBW). The World Health Organization aimed to achieve a 30% reduction in the number of LBW infants by the year 2025. In this study, we aimed to determine the incidence and determinants of LBW infants among pregnant mothers attending government health clinics in Peninsular Malaysia.
MATERIAL AND METHODS: A prospective cohort study "Relative Risk of Determinants of Adverse Pregnancy Outcomes Among Pregnant Mothers Attending Government Health Clinics, Peninsular Malaysia, PEN-MUM" was conducted from March 2022 until March 2023 at 20 government health clinics in Peninsular Malaysia that were randomly selected through a multistage sampling method. Malaysian pregnant mothers between 18 and 49 years old were recruited at 12-18 weeks of gestation and followed up at three time points: 1 (24-28 weeks of gestation), 2 (36-40 weeks of gestation), and 3 (post-delivery). Eight exposure factors of LBW were studied: gestational weight gain, dengue infection, urinary tract infection, COVID-19 infection, gestational hypertension, preeclampsia, maternal anemia, and gestational diabetes mellitus (GDM).
RESULTS: Among 507 participants enrolled in the cohort, 40 were lost to follow-up. A total of 467 were included in the final analysis, giving an attrition rate of 7.9%. The incidence of LBW infants in Peninsular Malaysia was 14.3%. After adjusting for three covariates (ethnicity, employment status, and gestational age at birth), three determinants of LBW were identified. The risk of giving birth to LBW infants was higher among those with inadequate gestational weight gain (aRR = 2.86, 95% CI: 1.12, 7.37, p = 0.03), gestational hypertension (aRR = 4.12; 95% CI: 1.66, 10.43; p = 0.002), and GDM (aRR = 2.21; 95% CI: 1.18, 4.14; p = 0.013) during the second and third trimesters.
CONCLUSIONS: The incidence of LBW infants in Peninsular Malaysia can be considered high. Having inadequate gestational weight gain, gestational hypertension, and GDM in the second and third trimesters increased the risk of LBW infants by threefold, fivefold, and twofold respectively. Thus, intervention strategies should target prevention, early detection, and treatment of gestational hypertension and GDM, as well as promoting adequate weight gain during antenatal care.
PURPOSE: To provide an intravaginal insoluble contraceptive suppository which contains freeze-dried foam and contraceptive agents, is easy to handle, and is long in potency. CONSTITUTION: The freeze-dried water-soluble foam and the contraceptive agents (e.g.: nonoxinol-9) are incorporated into the contraceptive suppository. The density of the suppository is 0.001 to 0.1 g/cc and the dissolution time is at least 2 hours and provides the excellent protection for pregnancy in 24 hours at the longest during this time. The contraceptive agents are incorporated at a concn. of 1 to 25% in the dispersion and at 20 to 95 wt.% of the dry suppository. Water soluble polyer (e.g.: hydoxypropyl methyl cellulose) is added to the dispersant at 1 to 20 concn. Another polymer, such as zetatin, antiseptics, fillers, excipients, binder, etc., are properly compounded with the suppository in addition to the above and the mixture is manufactured to the suppository.  The bioinvasive intravaginal contraceptive suppository which is sustained and or controlled in the release of the contraceptive agents, affords the protection for the pregnancy for the specified period of time and is not easily expelled is obtd. Further, the easy control of the dissolution time of the suppository and the delivery ratio of the medicines is possible.
Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of vascular smooth muscle cells (VSMC) or vascular endothelial cells (VEC). Pro-resolving lipid mediators that find use in the subject methods include derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids, such as resolvins, protectins, lipoxins and maresins and their therapeutically stable analogs. Also provided are vascular devices and compositions for use in the subject methods. Such methods, devices and compositions find use in a variety of applications, including applications related to treatment of vascular injuries and vascular scarring (e.g., restenosis), and applications related to chronic inflammatory diseases of the vascular wall .
PURPOSE:To obtain an aqueous coenzyme Q pharmaceutical, containing many ribosomes of a specific amount of lecithin containing a specified amount of dispersed coenzyme Q in an emulsified state, having improved absorbability substantially without ethanol with no limitation on use. CONSTITUTION:One pt.wt. coenzyme Q and 15-100pts.wt. lecithin are dissolved in a solvent capable of dissolving both substances easily, preferably an organic solvent having a dipole moment value <=1.5 (in the liquid phase) and a high volatility or a 3-7C carboxylic ester, and then the solvent is removed. The resultant residue is then emulsified in an aqueous solvent to give an aqueous coenzyme Q pharmaceutical containing many ribosomes of lecithin containing dispersed coenzyme Q in the proportion described above in an emulsified state and substantially no ethanol. The resultant pharmaceutical has improved absorbability in digestive tracts and is useful for the treatment of angina pectoris, etc. by the oral administration.